Literature DB >> 21175993

Roles of intrinsic angiogenesis inhibitor, vasohibin, in cervical carcinomas.

Kousuke Yoshinaga1, Kiyoshi Ito, Takuya Moriya, Satoru Nagase, Tadao Takano, Hitoshi Niikura, Hironobu Sasano, Nobuo Yaegashi, Yasufumi Sato.   

Abstract

The aim of the present study is to clarify the critical roles of vasohibin in cervical carcinomas. We investigated the expression ratios of vasohibin and vascular endothelial growth factor (VEGF) receptor-2 on endothelium and microvessel density, lymphatic vessel density (LVD) by immunohistochemistry. Sixty-one squamous cell carcinoma (SCC), 18 mucinous adenocarcinoma (Adenocarcinoma), 38 carcinoma in situ (CIS), and 35 normal cervical epithelium were collected. We investigated the expression of vasohibin and compared it with the expression of VEGF receptor-2 (VEGFR-2, KDR/flk-1), and CD34 in the stromal endothelium. Expression of VEGF was counted using the histological score (H score). D2-40 was used as a marker for lymphatic endothelial cells to investigate LVD. The microvessel density of the normal cervical epithelium was significantly lower than that of CIS, SCC, and Adenocarcinoma (P < 0.05). The expression ratio of vasohibin in the normal cervical epithelium was significantly lower than that of SCC and Adenocarcinoma (P < 0.05). The expression ratio of VEGFR-2 of the normal cervical epithelium was significantly lower than that of SCC and Adenocarcinoma (P < 0.05). The LVD of the normal cervical epithelium was significantly lower than that of CIS, SCC, and Adenocarcinoma (P < 0.05). For normal cervical epithelium, CIS, and SCC, there was a moderate correlation between the expression percentage of vasohibin and the expression percentage of VEGFR-2 (P < 0.05, r(2) = 0.3018). This is the first study to elucidate the correlation between the expression of vasohibin in the stromal endothelial cells and the expression of VEGFR-2 in human cervical carcinomas.
© 2010 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21175993     DOI: 10.1111/j.1349-7006.2010.01812.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  17 in total

Review 1.  Exploring the therapeutic rationale for angiogenesis blockade in cervical cancer.

Authors:  Lauren S Krill; Krishnansu S Tewari
Journal:  Clin Ther       Date:  2015-01-01       Impact factor: 3.393

2.  Association between TAp73, p53 and VASH1 expression in lung adenocarcinoma.

Authors:  Meng Wu; Zhihua Zhang; Fangxu Ma; Xiulong Zhang; Zhilin Zhang; Jianhua Tang; Ping Chen; Chunyan Zhou; Weiping Wang
Journal:  Oncol Lett       Date:  2018-01-31       Impact factor: 2.967

3.  Vasohibin-1 expression detected by immunohistochemistry correlates with prognosis in non-small cell lung cancer.

Authors:  Tao Zhang; Ting-Ting Yu; Dong-Ming Zhang; Xiao-Ming Hou; Xiao-Jun Liu; Da Zhao; Li Shan
Journal:  Med Oncol       Date:  2014-04-20       Impact factor: 3.064

Review 4.  The vasohibin family: a novel family for angiogenesis regulation.

Authors:  Yasufumi Sato
Journal:  J Biochem       Date:  2012-10-25       Impact factor: 3.387

Review 5.  Clinical Trials of Antiangiogenesis Therapy in Recurrent/Persistent and Metastatic Cervical Cancer.

Authors:  Jill K Alldredge; Krishnansu S Tewari
Journal:  Oncologist       Date:  2016-03-29

6.  Reduced expression of vasohibin-1 is associated with clinicopathological features in renal cell carcinoma.

Authors:  Guangning Zhao; Yuming Yang; Yang Tang; Ruifa Han; Yan Sun
Journal:  Med Oncol       Date:  2012-08-03       Impact factor: 3.064

7.  Role of macrophage migration inhibitory factor in mesenchymal epithelial transition of cervical carcinoma cells.

Authors:  Fangfang Guo; Xueqi Fu; Jili Yang; Xueying Zhang; Dezhi Liu; Wenjuan Feng; Jinyu Liu; Jinhong Qi; Huifang Cao; Li Qi; Jingyuan Ren
Journal:  Int J Clin Exp Pathol       Date:  2017-09-01

8.  Expression of vasohibin-1 and -2 predicts poor prognosis among patients with squamous cell carcinoma of the esophagus.

Authors:  Yamato Ninomiya; Soji Ozawa; Junya Oguma; Akihito Kazuno; Miho Nitta; Hiroshi Kajiwara; Yasufumi Sato
Journal:  Oncol Lett       Date:  2018-08-01       Impact factor: 2.967

9.  The angiogenesis regulator vasohibin-1 inhibits ovarian cancer growth and peritoneal dissemination and prolongs host survival.

Authors:  Yoshifumi Takahashi; Yasushi Saga; Takahiro Koyanagi; Yuji Takei; Sizuo Machida; Akiyo Taneichi; Hiroaki Mizukami; Yasufumi Sato; Shigeki Matsubara; Hiroyuki Fujiwara
Journal:  Int J Oncol       Date:  2015-10-08       Impact factor: 5.650

10.  The prognostic significance of vasohibin-1 expression in patients with prostate cancer.

Authors:  T Kosaka; Y Miyazaki; A Miyajima; S Mikami; Y Hayashi; N Tanaka; H Nagata; E Kikuchi; K Nakagawa; Y Okada; Y Sato; M Oya
Journal:  Br J Cancer       Date:  2013-04-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.